Key facts
- It has raised $365.0M; the latest was Later Stage VC ($75.0M) in Jan 2026.
- Notable investors include Goldman Sachs Asset Management, Oxford Science Enterprises, Forbion, Advent Life Sciences, Retinal Degeneration Fund — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Beacon Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Beacon Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Beacon Therapeutics
Operator of a clinical-stage biotechnology company intended to treat patients with rare lung and eye diseases. The company utilizes a proprietary gene therapy platform to develop transformational genetic therapies for patients with rare and debilitating diseases, with a focus on ophthalmology, enabling clinicians to improve the lives of patients with severe conditions significantly.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2023
- Employees
- 91
- Website
- beacontx.com/
- Ownership
- Privately Held (backing)
Beacon Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Beacon Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Beacon Therapeutics in its N-PORT filings yet. We sweep new filings monthly.